The OPTIC Trial: A Ponatinib Dose-Ranging Study in Chronic Myeloid Leukemia

News
Video

Michael Mauro, MD, presents data on a phase 2 ponatinib dose-ranging study in chronic-phase CML.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
    • Chapters
    • descriptions off, selected
    • captions off, selected
      Recent Videos
      Both clinicians and patients should have as much information as possible to participate in shared decision-making for CLL care, says Jacob D. Soumerai, MD.
      CLL Workshop Emphasizes Engaging Conversations on Shared Treatment Planning
      Sequencing different treatments in the first 3 lines of therapy represents a challenge in chronic lymphocytic leukemia, according to Deborah Stephens, DO.
      Navigating Treatment Decision-Making Challenges in CLL Management
      Compared with second-generation tyrosine kinase inhibitors, asciminib was better tolerated in patients with chronic myeloid leukemia.
      Asciminib Appears to Benefit All Chronic Myeloid Leukemia Subgroups
      Bulkiness of disease did not appear to impact PFS outcomes with ibrutinib plus venetoclax in the phase 2 CAPTIVATE study.
      Undetected MRD Confers Improved PFS With Ibrutinib Combo in CLL/SLL
      A panel of 3 experts on CML
      Advancing CML Management Towards an Ideal Patient Journey
      A panel of 3 experts on CML
      Ensuring Informed CML Care from Diagnosis Onward
      A panel of 3 experts on CML
      CML Treatment: Scenarios that Necessitate Switching Therapy
      A panel of 3 experts on CML
      When CML Therapy Shifts: Collaborative Approaches to Treatment Changes
      A panel of 3 experts on CML
      Open Dialogue in CML Care: Setting Expectations, Managing Side Effects, and Optimizing Patient Quality of Life
      A panel of 3 experts on CML
      Starting CML Treatment: Collaborative Choices for Better Outcomes
      Related Content
      Revumenib Yields Meaningful Benefit in NPM1-Mutated Acute Myeloid Leukemia | Image Credit: © LASZLO - stock.adobe.com.

      Revumenib Yields Meaningful Benefit in NPM1-Mutated Acute Myeloid Leukemia

      Russ Conroy
      May 9th 2025
      Article

      Phase 2 data support the potential of revumenib to advance the standard of care for patients with relapsed/refractory NPM1-mutated acute myeloid leukemia.

      Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

      Managing Cytokine Release Syndrome in Patients on CAR T-Cell Therapy

      Elizabeth Shpall, MD
      May 29th 2019
      Podcast

      Ahead of the ASCO Annual Meeting, we discuss the assessment and management of cytokine release syndrome in patients with cancer with Elizabeth Shpall, MD.

      The CHMP Recommends Acalabrutinib Combos for Approval in Untreated CLL

      The CHMP Recommends Acalabrutinib Combos for Approval in Untreated CLL

      Tim Cortese
      April 30th 2025
      Article

      Results from the phase 3 AMPLIFY trial showed that acalabrutinib plus venetoclax, with or without obinutuzumab, prolonged PFS vs chemoimmunotherapy in CLL.

      Immunotherapy Approaches in AML

      Immunotherapy Approaches in AML

      Naval Daver, MD
      January 17th 2019
      Podcast

      Cancer Network sat down with Dr. Naval Daver to discuss advancements and discoveries in immunotherapy for AML patients.

      A network meta-analysis of 3 clinical trials sought to compare zanubrutinib vs approved BTKis in relapsed/refractory chronic lymphocytic leukemia.

      Zanubrutinib Shows Enhanced Efficacy vs Approved BTKis in R/R CLL

      Roman Fabbricatore
      April 21st 2025
      Article

      A network meta-analysis of 3 clinical trials sought to compare zanubrutinib vs approved BTKis in relapsed/refractory chronic lymphocytic leukemia.

      Tambiciclib was well tolerated in patients with acute myeloid leukemia with myelodysplastic-related changes, and no new safety signals were observed.

      Tambiciclib Displays Survival Benefit, Enhanced ORR in AML-MRC

      Roman Fabbricatore
      April 9th 2025
      Article

      Tambiciclib was well tolerated in patients with acute myeloid leukemia with myelodysplastic-related changes, and no new safety signals were observed.